Biodegradable-polymer versus durable-polymer drug-eluting stents in left main percutaneous coronary intervention: final results of the randomised IDEAL-LM trial.
作者信息
Griffioen Alexander M, van Geuns Robert-Jan M, McEntegart Margaret B, Merkulov Evgeny, Krestyaninov Oleg, Kretov Evgeny, Lesiak Maciej, O'Kane Peter, Hanratty Colm G, Bressollette Erwan, Silvestri Marc, Wlodarczak Adrian, Barragan Paul, Anderson Richard, Protopopov Aleksey, Peace Aaron, Menown Ian, Rocchiccioli Paul, Onuma Yoshinobu, Oldroyd Keith G
机构信息
Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Golden Jubilee National Hospital, Glasgow, United Kingdom.
出版信息
EuroIntervention. 2025 Jun 2;21(11):e639-e641. doi: 10.4244/EIJ-D-24-00918.
Abstract
摘要
相似文献
1
Biodegradable-polymer versus durable-polymer drug-eluting stents in left main percutaneous coronary intervention: final results of the randomised IDEAL-LM trial.左主干经皮冠状动脉介入治疗中生物可降解聚合物与耐用聚合物药物洗脱支架的比较：随机IDEAL-LM试验的最终结果
EuroIntervention. 2025 Jun 2;21(11):e639-e641. doi: 10.4244/EIJ-D-24-00918.
2
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial.接受经皮冠状动脉介入治疗患者中无聚合物与可生物降解聚合物药物洗脱支架的比较：一项评估者盲法、非劣效性随机对照试验
EuroIntervention. 2025 Jan 6;21(1):58-72. doi: 10.4244/EIJ-D-24-00657.
3
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.超薄支架、可生物降解聚合物、西罗莫司洗脱支架与薄支架、耐用聚合物、依维莫司洗脱支架经皮冠状动脉血运重建：BIOSCIENCE 随机试验 5 年结果。
Lancet. 2018 Sep 1;392(10149):737-746. doi: 10.1016/S0140-6736(18)31715-X. Epub 2018 Aug 28.
4
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.左主干冠状动脉疾病患者中使用 4 个月双联抗血小板治疗的可生物吸收聚合物药物洗脱支架与使用 12 个月双联抗血小板治疗的耐用聚合物药物洗脱支架的比较：IDEAL-LM 随机试验。
EuroIntervention. 2022 Apr 22;17(18):1467-1476. doi: 10.4244/EIJ-D-21-00514.
5
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.临床实践中第一代和第二代可降解聚合物药物洗脱支架与生物可降解聚合物依维莫司洗脱支架的安全性和疗效结局：综合网络荟萃分析。
BMJ. 2013 Nov 6;347:f6530. doi: 10.1136/bmj.f6530.
6
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.与含有不可降解聚合物的西罗莫司洗脱支架相比，含可生物降解聚合物的比伐卢定洗脱支架在冠状动脉疾病患者中具有更好的安全性和降低支架血栓形成的风险：LEADERS（雷帕霉素从不可降解到可降解涂层支架洗脱）随机、非劣效性试验的最终 5 年报告。
JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.
7
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.超薄支架可生物降解聚合物西罗莫司洗脱支架与耐用聚合物依维莫司洗脱支架经皮冠状动脉血运重建（BIOSCIENCE）：一项随机、单盲、非劣效性试验。
Lancet. 2014 Dec 13;384(9960):2111-22. doi: 10.1016/S0140-6736(14)61038-2. Epub 2014 Sep 1.
8
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.生物可降解聚合物西罗莫司洗脱支架与持久性聚合物依维莫司洗脱支架治疗 ST 段抬高型心肌梗死的长期疗效：BIOSTEMI 随机优势试验 5 年随访结果。
Lancet. 2023 Nov 25;402(10416):1979-1990. doi: 10.1016/S0140-6736(23)02197-9. Epub 2023 Oct 25.
9
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.生物可降解聚合物西罗莫司洗脱支架与耐久性聚合物依维莫司洗脱支架在 ST 段抬高型心肌梗死患者中的比较（BIOSTEMI）：一项单盲、前瞻性、随机优效性试验。
Lancet. 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X. Epub 2019 Sep 2.
10
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.非常薄的支撑物可生物降解聚合物依维莫司洗脱和西罗莫司洗脱支架与全人群冠心病使用耐用聚合物佐他莫司洗脱支架（BIO-RESORT）：一项三臂、随机、非劣效试验。
Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30.
本文引用的文献
1
2024 ESC Guidelines for the management of chronic coronary syndromes.2024年欧洲心脏病学会慢性冠状动脉综合征管理指南
Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177.
2
Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.左主干冠状动脉疾病患者中使用 4 个月双联抗血小板治疗的可生物吸收聚合物药物洗脱支架与使用 12 个月双联抗血小板治疗的耐用聚合物药物洗脱支架的比较：IDEAL-LM 随机试验。
EuroIntervention. 2022 Apr 22;17(18):1467-1476. doi: 10.4244/EIJ-D-21-00514.
3
Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗无保护左主干狭窄：NOBLE 随机非劣效性试验的 5 年更新结果。
Lancet. 2020 Jan 18;395(10219):191-199. doi: 10.1016/S0140-6736(19)32972-1. Epub 2019 Dec 23.
4
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.左主干冠状动脉疾病经皮冠状动脉介入治疗或冠状动脉旁路移植术后 5 年的结果。
N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28.
5
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗无保护左主干狭窄（NOBLE）：一项前瞻性、随机、开放标签、非劣效性试验。
Lancet. 2016 Dec 3;388(10061):2743-2752. doi: 10.1016/S0140-6736(16)32052-9. Epub 2016 Oct 31.
6
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.依维莫司洗脱支架或旁路移植术治疗左主干冠状动脉疾病。
N Engl J Med. 2016 Dec 8;375(23):2223-2235. doi: 10.1056/NEJMoa1610227. Epub 2016 Oct 31.
Zotero 插件